Effectiveness of GeneX for the management of defects in fractures
Research type
Research Study
Full title
Effectiveness of the management of bony defects/dead space in fractures with the use of GeneX- an absorbable synthetic bone graft
IRAS ID
187933
Contact name
Hemant Sharma
Contact email
Sponsor organisation
Research and Development Office
Duration of Study in the UK
0 years, 7 months, 29 days
Research summary
Bone grafts are commonly used in the surgical management of fractures or non unions. They are used to fill cavities and help promote bone growth and fracture healing. Fractures such as periarticular fractures, ones that extend into a joint, often have depression (compression) of the joint surface and when this joint surface is reconstructed to its normal anatomical alignment it often leaves a cavity or dead space underneath. Bone graft is used to fill this space, supporting the elevated joint surface and promote new bone formation, helping maintain alignment through its use as a mechanical scaffold and provides a structure for new cells to form new bone growth in the healing process.
There are different types of bone graft available. GeneX is a synthetic graft that contains Beta-tri-calcium phosphate and calcium sulphate. It is an absorbable, osteoconductive scaffold used for accelerating bone growth. Its properties are designed to promote bone healing. This study aims to look at the effectiveness of GeneX in maintaining the joint surface (preventing collapse) and healing of fractures in patients who had genex used in their surgery at Hull Royal Infirmary. The primary aim of this study is to assess the effectiveness of GeneX in maintaining the position of elevated articular (joint surface) segment and bone healing.REC name
South Central - Hampshire A Research Ethics Committee
REC reference
15/SC/0533
Date of REC Opinion
28 Sep 2015
REC opinion
Further Information Favourable Opinion